ID   EBP_HUMAN               Reviewed;         230 AA.
AC   Q15125; Q6FGL3; Q6IBI9;
DT   18-OCT-2001, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   15-MAR-2017, entry version 155.
DE   RecName: Full=3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase;
DE            EC=5.3.3.5 {ECO:0000269|PubMed:12760743, ECO:0000269|PubMed:8798407, ECO:0000269|PubMed:9894009};
DE   AltName: Full=Cholestenol Delta-isomerase;
DE   AltName: Full=Delta(8)-Delta(7) sterol isomerase;
DE            Short=D8-D7 sterol isomerase;
DE   AltName: Full=Emopamil-binding protein;
GN   Name=EBP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=7706302; DOI=10.1074/jbc.270.13.7551;
RA   Hanner M., Moebius F.F., Weber F., Grabner M., Striessnig J.,
RA   Glossmann H.;
RT   "Phenylalkylamine Ca2+ antagonist binding protein. Molecular cloning,
RT   tissue distribution, and heterologous expression.";
RL   J. Biol. Chem. 270:7551-7557(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cervix, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   CATALYTIC ACTIVITY, FUNCTION, AND PATHWAY.
RX   PubMed=8798407; DOI=10.1074/jbc.271.37.22434;
RA   Silve S., Dupuy P.H., Labit-Lebouteiller C., Kaghad M., Chalon P.,
RA   Rahier A., Taton M., Lupker J., Shire D., Loison G.;
RT   "Emopamil-binding protein, a mammalian protein that binds a series of
RT   structurally diverse neuroprotective agents, exhibits delta8-delta7
RT   sterol isomerase activity in yeast.";
RL   J. Biol. Chem. 271:22434-22440(1996).
RN   [7]
RP   CATALYTIC ACTIVITY, FUNCTION, PATHWAY, AND MUTAGENESIS.
RX   PubMed=9894009; DOI=10.1021/bi981804i;
RA   Moebius F.F., Soellner K.E.M., Fiechtner B., Huck C.W., Bonn G.,
RA   Glossmann H.;
RT   "Histidine77, glutamic acid81, glutamic acid123, threonine126,
RT   asparagine194, and tryptophan197 of the human emopamil binding protein
RT   are required for in vivo sterol delta 8-delta 7 isomerization.";
RL   Biochemistry 38:1119-1127(1999).
RN   [8]
RP   SUBCELLULAR LOCATION.
RX   PubMed=10406945; DOI=10.1046/j.1432-1327.1999.00500.x;
RA   Dussossoy D., Carayon P., Belugou S., Feraut D., Bord A., Goubet C.,
RA   Roque C., Vidal H., Combes T., Loison G., Casellas P.;
RT   "Colocalization of sterol isomerase and sigma(1) receptor at
RT   endoplasmic reticulum and nuclear envelope level.";
RL   Eur. J. Biochem. 263:377-386(1999).
RN   [9]
RP   INVOLVEMENT IN MEND, VARIANT MEND PRO-18, AND CHARACTERIZATION OF
RP   VARIANT MEND PRO-18.
RX   PubMed=12503101; DOI=10.1002/ajmg.a.10849;
RA   Milunsky J.M., Maher T.A., Metzenberg A.B.;
RT   "Molecular, biochemical, and phenotypic analysis of a hemizygous male
RT   with a severe atypical phenotype for X-linked dominant Conradi-
RT   Hunermann-Happle syndrome and a mutation in EBP.";
RL   Am. J. Med. Genet. A 116A:249-254(2003).
RN   [10]
RP   CATALYTIC ACTIVITY, FUNCTION, PATHWAY, AND MUTAGENESIS OF TYR-111;
RP   MET-121 AND PHE-189.
RX   PubMed=12760743; DOI=10.1042/BJ20030465;
RA   Moebius F.F., Fitzky B.U., Wietzorrek G., Haidekker A., Eder A.,
RA   Glossmann H.;
RT   "Cloning of an emopamil-binding protein (EBP)-like protein that lacks
RT   sterol delta8-delta7 isomerase activity.";
RL   Biochem. J. 374:229-237(2003).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [12]
RP   INVOLVEMENT IN MEND, VARIANT MEND CYS-47, AND CHARACTERIZATION OF
RP   VARIANT MEND CYS-47.
RX   PubMed=20949533; DOI=10.1002/ajmg.a.33674;
RA   Furtado L.V., Bayrak-Toydemir P., Hulinsky B., Damjanovich K.,
RA   Carey J.C., Rope A.F.;
RT   "A novel X-linked multiple congenital anomaly syndrome associated with
RT   an EBP mutation.";
RL   Am. J. Med. Genet. A 152A:2838-2844(2010).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT THR-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [15]
RP   VARIANT CDPX2 GLN-110.
RX   PubMed=10391218; DOI=10.1038/10350;
RA   Derry J.M.J., Gormally E., Means G.D., Zhao W., Meindl A.,
RA   Kelley R.I., Boyd Y., Herman G.E.;
RT   "Mutations in a delta(8)-delta(7) sterol isomerase in the tattered
RT   mouse and X-linked dominant chondrodysplasia punctata.";
RL   Nat. Genet. 22:286-290(1999).
RN   [16]
RP   VARIANTS CDPX2 LYS-80 AND HIS-147.
RX   PubMed=10391219; DOI=10.1038/10357;
RA   Braverman N., Lin P., Moebius F.F., Obie C., Moser A., Glossmann H.,
RA   Wilcox W.R., Rimoin D.L., Smith M., Kratz L., Kelley R.I., Valle D.;
RT   "Mutations in the gene encoding 3-beta-hydroxysteroid-
RT   delta(8),delta(7)-isomerase cause X-linked dominant Conradi-Hunermann
RT   syndrome.";
RL   Nat. Genet. 22:291-294(1999).
RN   [17]
RP   VARIANT CDPX2 HIS-147.
RX   PubMed=10942423; DOI=10.1093/hmg/9.13.1951;
RA   Has C., Bruckner-Tuderman L., Muller D., Floeth M., Folkers E.,
RA   Donnai D., Traupe H.;
RT   "The Conradi-Hunermann-Happle syndrome (CDPX2) and emopamil binding
RT   protein: novel mutations, and somatic and gonadal mosaicism.";
RL   Hum. Mol. Genet. 9:1951-1955(2000).
RN   [18]
RP   VARIANT CDPX2 GLY-147.
RX   PubMed=11493318; DOI=10.1034/j.1600-0625.2001.100409.x;
RA   Becker K., Csikos M., Horvath A., Karpati S.;
RT   "Identification of a novel mutation in 3beta-hydroxysteroid-Delta8-
RT   Delta7-isomerase in a case of Conradi-Hunermann-Happle syndrome.";
RL   Exp. Dermatol. 10:286-289(2001).
RN   [19]
RP   VARIANT CDPX2 LYS-103.
RX   PubMed=18176751; DOI=10.2340/00015555-0337;
RA   Kolb-Maeurer A., Grzeschik K.H., Haas D., Broecker E.B., Hamm H.;
RT   "Conradi-Huenermann-Happle syndrome (X-linked dominant
RT   chondrodysplasia punctata) confirmed by plasma sterol and mutation
RT   analysis.";
RL   Acta Derm. Venereol. 88:47-51(2008).
RN   [20]
RP   VARIANT MEND ARG-47, AND CHARACTERIZATION OF VARIANT MEND ARG-47.
RX   PubMed=24459067; DOI=10.1002/ajmg.a.36368;
RA   Hartill V.L., Tysoe C., Manning N., Dobbie A., Santra S., Walter J.,
RA   Caswell R., Koster J., Waterham H., Hobson E.;
RT   "An unusual phenotype of X-linked developmental delay and extreme
RT   behavioral difficulties associated with a mutation in the EBP gene.";
RL   Am. J. Med. Genet. A 164A:907-914(2014).
RN   [21]
RP   VARIANT MEND ASN-75, AND CHARACTERIZATION OF VARIANT MEND ASN-75.
RX   PubMed=24700572; DOI=10.1002/ajmg.a.36508;
RA   Barboza-Cerda M.C., Wong L.J., Martinez-de-Villarreal L.E.,
RA   Zhang V.W., Dector M.A.;
RT   "A novel EBP c.224T>A mutation supports the existence of a male-
RT   specific disorder independent of CDPX2.";
RL   Am. J. Med. Genet. A 164A:1642-1647(2014).
RN   [22]
RP   VARIANT CDPX2 HIS-147.
RX   PubMed=25814754; DOI=10.4103/0019-5154.152570;
RA   Ozyurt K., Subasioglu A., Ozturk P., Inci R., Ozkan F., Bueno E.,
RA   Canueto J., Gonzalez Sarmiento R.;
RT   "Emopamil binding protein mutation in conradi-huenermann-happle
RT   syndrome representing plaque-type psoriasis.";
RL   Indian J. Dermatol. 60:216-216(2015).
CC   -!- FUNCTION: Catalyzes the conversion of Delta(8)-sterols to their
CC       corresponding Delta(7)-isomers. {ECO:0000269|PubMed:12760743,
CC       ECO:0000269|PubMed:8798407, ECO:0000269|PubMed:9894009}.
CC   -!- CATALYTIC ACTIVITY: 5-alpha-cholest-7-en-3-beta-ol = 5-alpha-
CC       cholest-8-en-3-beta-ol. {ECO:0000269|PubMed:12760743,
CC       ECO:0000269|PubMed:8798407, ECO:0000269|PubMed:9894009}.
CC   -!- PATHWAY: Steroid biosynthesis; cholesterol biosynthesis.
CC       {ECO:0000269|PubMed:12760743, ECO:0000269|PubMed:8798407,
CC       ECO:0000269|PubMed:9894009}.
CC   -!- INTERACTION:
CC       O43889-2:CREB3; NbExp=3; IntAct=EBI-3915253, EBI-625022;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:10406945}; Multi-pass membrane protein
CC       {ECO:0000305}. Nucleus envelope {ECO:0000269|PubMed:10406945}.
CC       Cytoplasmic vesicle {ECO:0000269|PubMed:10406945}. Note=During
CC       interphase, detected on the endoplasmic reticulum and the nuclear
CC       envelope. During mitosis, detected on cytoplasmic vesicles.
CC       {ECO:0000269|PubMed:10406945}.
CC   -!- DISEASE: Chondrodysplasia punctata 2, X-linked dominant (CDPX2)
CC       [MIM:302960]: A clinically and genetically heterogeneous disorder
CC       characterized by punctiform calcification of the bones. The key
CC       clinical features of CDPX2 are chondrodysplasia punctata, linear
CC       ichthyosis, cataracts and short stature. CDPX2 is a rare disorder
CC       of defective cholesterol biosynthesis, biochemically characterized
CC       by an increased amount of 8-dehydrocholesterol and cholest-8(9)-
CC       en-3-beta-ol in the plasma and tissues.
CC       {ECO:0000269|PubMed:10391218, ECO:0000269|PubMed:10391219,
CC       ECO:0000269|PubMed:10942423, ECO:0000269|PubMed:11493318,
CC       ECO:0000269|PubMed:18176751, ECO:0000269|PubMed:25814754}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: MEND syndrome (MEND) [MIM:300960]: An X-linked recessive
CC       disorder associated with a defect in sterol biosynthesis. Disease
CC       manifestations and severity are highly variable. Clinical features
CC       include intellectual disability, short stature, scoliosis, digital
CC       abnormalities, cataracts, and dermatologic abnormalities.
CC       {ECO:0000269|PubMed:12503101, ECO:0000269|PubMed:20949533,
CC       ECO:0000269|PubMed:24459067, ECO:0000269|PubMed:24700572}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- MISCELLANEOUS: Binds to the phenylalkylamine calcium-ion
CC       antagonist emopamil, an anti-ischemic drug.
CC   -!- SIMILARITY: Belongs to the EBP family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z37986; CAA86068.1; -; mRNA.
DR   EMBL; CR456815; CAG33096.1; -; mRNA.
DR   EMBL; CR542094; CAG46891.1; -; mRNA.
DR   EMBL; AF196969; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF196972; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471224; EAW50773.1; -; Genomic_DNA.
DR   EMBL; BC001549; AAH01549.1; -; mRNA.
DR   EMBL; BC001572; AAH01572.1; -; mRNA.
DR   EMBL; BC046501; AAH46501.1; -; mRNA.
DR   CCDS; CCDS14300.1; -.
DR   PIR; B56122; B56122.
DR   RefSeq; NP_006570.1; NM_006579.2.
DR   UniGene; Hs.30619; -.
DR   ProteinModelPortal; Q15125; -.
DR   BioGrid; 115921; 38.
DR   IntAct; Q15125; 18.
DR   STRING; 9606.ENSP00000417052; -.
DR   BindingDB; Q15125; -.
DR   ChEMBL; CHEMBL4931; -.
DR   DrugBank; DB00675; Tamoxifen.
DR   SwissLipids; SLP:000001209; -.
DR   iPTMnet; Q15125; -.
DR   PhosphoSitePlus; Q15125; -.
DR   BioMuta; EBP; -.
DR   DMDM; 17374795; -.
DR   EPD; Q15125; -.
DR   MaxQB; Q15125; -.
DR   PaxDb; Q15125; -.
DR   PeptideAtlas; Q15125; -.
DR   PRIDE; Q15125; -.
DR   TopDownProteomics; Q15125; -.
DR   DNASU; 10682; -.
DR   Ensembl; ENST00000495186; ENSP00000417052; ENSG00000147155.
DR   GeneID; 10682; -.
DR   KEGG; hsa:10682; -.
DR   UCSC; uc004djx.5; human.
DR   CTD; 10682; -.
DR   DisGeNET; 10682; -.
DR   GeneCards; EBP; -.
DR   GeneReviews; EBP; -.
DR   HGNC; HGNC:3133; EBP.
DR   HPA; HPA003130; -.
DR   MalaCards; EBP; -.
DR   MIM; 300205; gene.
DR   MIM; 300960; phenotype.
DR   MIM; 302960; phenotype.
DR   neXtProt; NX_Q15125; -.
DR   OpenTargets; ENSG00000147155; -.
DR   Orphanet; 352487; Digital anomalies - intellectual disability - short stature.
DR   Orphanet; 401973; MEND syndrome.
DR   Orphanet; 35173; X-linked dominant chondrodysplasia punctata.
DR   PharmGKB; PA27587; -.
DR   eggNOG; KOG4826; Eukaryota.
DR   eggNOG; ENOG41101ES; LUCA.
DR   GeneTree; ENSGT00530000063715; -.
DR   HOGENOM; HOG000204543; -.
DR   HOVERGEN; HBG018176; -.
DR   InParanoid; Q15125; -.
DR   KO; K01824; -.
DR   OMA; FVIHHET; -.
DR   OrthoDB; EOG091G0KCI; -.
DR   PhylomeDB; Q15125; -.
DR   TreeFam; TF314716; -.
DR   BioCyc; MetaCyc:ENSG00000147155-MONOMER; -.
DR   BRENDA; 5.3.3.5; 2681.
DR   Reactome; R-HSA-6807047; Cholesterol biosynthesis via desmosterol.
DR   Reactome; R-HSA-6807062; Cholesterol biosynthesis via lathosterol.
DR   SABIO-RK; Q15125; -.
DR   UniPathway; UPA00063; -.
DR   GenomeRNAi; 10682; -.
DR   PRO; PR:Q15125; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000147155; -.
DR   CleanEx; HS_EBP; -.
DR   ExpressionAtlas; Q15125; baseline and differential.
DR   Genevisible; Q15125; HS.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-KW.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005635; C:nuclear envelope; IDA:UniProtKB.
DR   GO; GO:0000247; F:C-8 sterol isomerase activity; IEA:Ensembl.
DR   GO; GO:0047750; F:cholestenol delta-isomerase activity; IEA:UniProtKB-EC.
DR   GO; GO:0015238; F:drug transmembrane transporter activity; TAS:ProtInc.
DR   GO; GO:0004769; F:steroid delta-isomerase activity; IDA:UniProtKB.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; TAS:ProtInc.
DR   GO; GO:0006695; P:cholesterol biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0033489; P:cholesterol biosynthetic process via desmosterol; TAS:Reactome.
DR   GO; GO:0033490; P:cholesterol biosynthetic process via lathosterol; TAS:Reactome.
DR   GO; GO:0008203; P:cholesterol metabolic process; TAS:ProtInc.
DR   GO; GO:0030097; P:hemopoiesis; IEA:Ensembl.
DR   GO; GO:0001501; P:skeletal system development; TAS:ProtInc.
DR   InterPro; IPR007905; EBP.
DR   InterPro; IPR033118; EXPERA.
DR   PANTHER; PTHR14207; PTHR14207; 1.
DR   Pfam; PF05241; EBP; 1.
DR   PROSITE; PS51751; EXPERA; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Cataract; Cholesterol biosynthesis;
KW   Cholesterol metabolism; Complete proteome; Cytoplasmic vesicle;
KW   Disease mutation; Dwarfism; Endoplasmic reticulum; Ichthyosis;
KW   Isomerase; Lipid biosynthesis; Lipid metabolism; Membrane; Nucleus;
KW   Reference proteome; Steroid biosynthesis; Steroid metabolism;
KW   Sterol biosynthesis; Sterol metabolism; Transmembrane;
KW   Transmembrane helix.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:25944712}.
FT   CHAIN         2    230       3-beta-hydroxysteroid-Delta(8),Delta(7)-
FT                                isomerase.
FT                                /FTId=PRO_0000174342.
FT   TRANSMEM     29     49       Helical. {ECO:0000255}.
FT   TRANSMEM     66     86       Helical. {ECO:0000255}.
FT   TRANSMEM    121    141       Helical. {ECO:0000255}.
FT   TRANSMEM    185    205       Helical. {ECO:0000255}.
FT   DOMAIN       61    204       EXPERA. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01087}.
FT   MOD_RES       2      2       N-acetylthreonine.
FT                                {ECO:0000244|PubMed:25944712}.
FT   VARIANT      18     18       L -> P (in MEND; patients have mildly
FT                                increased concentrations of plasma 8(9)-
FT                                cholestenol and 8-dehydrocholesterol;
FT                                probable hypomorphic mutation;
FT                                dbSNP:rs104894795).
FT                                {ECO:0000269|PubMed:12503101}.
FT                                /FTId=VAR_074633.
FT   VARIANT      47     47       W -> C (in MEND; patients have increased
FT                                concentrations of plasma 8(9)-
FT                                cholestenol, 8-dehydrocholesterol and 7-
FT                                dehydrocholesterol; probable hypomorphic
FT                                mutation; dbSNP:rs587783599).
FT                                {ECO:0000269|PubMed:20949533}.
FT                                /FTId=VAR_074634.
FT   VARIANT      47     47       W -> R (in MEND; patients have increased
FT                                concentrations of plasma 8-
FT                                dehydrocholesterol and 8(9)-cholestenol;
FT                                probable hypomorphic mutation).
FT                                {ECO:0000269|PubMed:24459067}.
FT                                /FTId=VAR_074635.
FT   VARIANT      75     75       I -> N (in MEND; patients have increased
FT                                plasma levels of 8(9)-cholestenol;
FT                                probable hypomorphic mutation;
FT                                dbSNP:rs797045153).
FT                                {ECO:0000269|PubMed:24700572}.
FT                                /FTId=VAR_074636.
FT   VARIANT      80     80       E -> K (in CDPX2; dbSNP:rs28936073).
FT                                {ECO:0000269|PubMed:10391219}.
FT                                /FTId=VAR_012105.
FT   VARIANT     103    103       E -> K (in CDPX2).
FT                                {ECO:0000269|PubMed:18176751}.
FT                                /FTId=VAR_074637.
FT   VARIANT     110    110       R -> Q (in CDPX2).
FT                                {ECO:0000269|PubMed:10391218}.
FT                                /FTId=VAR_012106.
FT   VARIANT     147    147       R -> G (in CDPX2).
FT                                {ECO:0000269|PubMed:11493318}.
FT                                /FTId=VAR_012107.
FT   VARIANT     147    147       R -> H (in CDPX2; dbSNP:rs28935174).
FT                                {ECO:0000269|PubMed:10391219,
FT                                ECO:0000269|PubMed:10942423,
FT                                ECO:0000269|PubMed:25814754}.
FT                                /FTId=VAR_012108.
FT   MUTAGEN      68     68       W->A: Reduces catalytic activity to less
FT                                than 35% of wild-type.
FT                                {ECO:0000269|PubMed:9894009}.
FT   MUTAGEN      75     75       I->A: Reduces catalytic activity to less
FT                                than 35% of wild-type.
FT                                {ECO:0000269|PubMed:9894009}.
FT   MUTAGEN      76     76       H->A: Reduces catalytic activity to less
FT                                than 10% of wild-type.
FT                                {ECO:0000269|PubMed:9894009}.
FT   MUTAGEN      80     80       E->A: Reduces catalytic activity to less
FT                                than 10% of wild-type.
FT                                {ECO:0000269|PubMed:9894009}.
FT   MUTAGEN     111    111       Y->W: Reduces catalytic activity to less
FT                                than 2% of wild-type.
FT                                {ECO:0000269|PubMed:12760743}.
FT   MUTAGEN     121    121       M->A: Reduces catalytic activity to less
FT                                than 35% of wild-type.
FT                                {ECO:0000269|PubMed:12760743}.
FT   MUTAGEN     121    121       M->V: No effect on catalytic activity.
FT                                {ECO:0000269|PubMed:12760743}.
FT   MUTAGEN     122    122       E->A: Reduces catalytic activity to less
FT                                than 10% of wild-type.
FT                                {ECO:0000269|PubMed:9894009}.
FT   MUTAGEN     125    125       T->A: Reduces catalytic activity to less
FT                                than 10% of wild-type.
FT                                {ECO:0000269|PubMed:9894009}.
FT   MUTAGEN     188    188       Y->A: Reduces catalytic activity to less
FT                                than 35% of wild-type.
FT                                {ECO:0000269|PubMed:9894009}.
FT   MUTAGEN     189    189       F->A: Reduces catalytic activity to less
FT                                than 35% of wild-type.
FT                                {ECO:0000269|PubMed:12760743}.
FT   MUTAGEN     189    189       F->L: No effect on catalytic activity.
FT                                {ECO:0000269|PubMed:12760743}.
FT   MUTAGEN     193    193       N->A: Reduces catalytic activity to less
FT                                than 10% of wild-type.
FT                                {ECO:0000269|PubMed:9894009}.
FT   MUTAGEN     196    196       W->A: Reduces catalytic activity to less
FT                                than 10% of wild-type.
FT                                {ECO:0000269|PubMed:9894009}.
FT   CONFLICT    187    188       FY -> IF (in Ref. 2; CAG33096).
FT                                {ECO:0000305}.
SQ   SEQUENCE   230 AA;  26353 MW;  3931A9DE3DBAFA04 CRC64;
     MTTNAGPLHP YWPQHLRLDN FVPNDRPTWH ILAGLFSVTG VLVVTTWLLS GRAAVVPLGT
     WRRLSLCWFA VCGFIHLVIE GWFVLYYEDL LGDQAFLSQL WKEYAKGDSR YILGDNFTVC
     METITACLWG PLSLWVVIAF LRQHPLRFIL QLVVSVGQIY GDVLYFLTEH RDGFQHGELG
     HPLYFWFYFV FMNALWLVLP GVLVLDAVKH LTHAQSTLDA KATKAKSKKN
//
